Immediate Impact
54 standout
Citing Papers
Cervical cancer therapies: Current challenges and future perspectives
2022 Standout
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
2022 Standout
Works of Marta Parera being referenced
A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
2008
Update on novel therapeutic agents for cervical cancer
2008
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Marta Parera | 153 | 109 | 75 | 9 | 313 | |
| Patrick W. Blake | 112 | 77 | 75 | 10 | 338 | |
| Fharat Raja | 150 | 40 | 189 | 10 | 295 | |
| H. M. Peters | 105 | 84 | 44 | 14 | 353 | |
| Adel El-Naggar | 93 | 77 | 76 | 9 | 340 | |
| Vivian M. Spaans | 123 | 73 | 30 | 13 | 342 | |
| Juhani Vartiainen | 76 | 56 | 57 | 15 | 334 | |
| Sidrah Shah | 163 | 40 | 104 | 11 | 361 | |
| Vaidehi Kannan | 83 | 130 | 26 | 15 | 347 | |
| Kellie S. Matthews | 163 | 72 | 111 | 16 | 322 | |
| J BELINSON | 79 | 110 | 142 | 11 | 347 |
All Works
Loading papers...